GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » PB Ratio

Humacyte (Humacyte) PB Ratio : 29.77 (As of Apr. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Humacyte's share price is $3.90. Humacyte's Book Value per Share for the quarter that ended in Dec. 2023 was $0.13. Hence, Humacyte's PB Ratio of today is 29.77.

The historical rank and industry rank for Humacyte's PB Ratio or its related term are showing as below:

HUMA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 32.08
Current: 30

During the past 4 years, Humacyte's highest PB Ratio was 32.08. The lowest was 0.00. And the median was 0.00.

HUMA's PB Ratio is ranked worse than
97.1% of 1310 companies
in the Biotechnology industry
Industry Median: 2.385 vs HUMA: 30.00

During the past 12 months, Humacyte's average Book Value Per Share Growth Rate was -88.40% per year.

Back to Basics: PB Ratio


Humacyte PB Ratio Historical Data

The historical data trend for Humacyte's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte PB Ratio Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- 6.11 1.86 21.68

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 3.90 4.84 8.18 21.68

Competitive Comparison of Humacyte's PB Ratio

For the Biotechnology subindustry, Humacyte's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's PB Ratio distribution charts can be found below:

* The bar in red indicates where Humacyte's PB Ratio falls into.



Humacyte PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Humacyte's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=3.90/0.131
=29.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Humacyte  (NAS:HUMA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Humacyte PB Ratio Related Terms

Thank you for viewing the detailed overview of Humacyte's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte (Humacyte) Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente officer: Chief Regulatory Officer 90 DAVIS STREET, SEEKONK MA 02771
Todd Pope director C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713

Humacyte (Humacyte) Headlines

From GuruFocus

Heather Prichard, COO of Humacyte Inc, Sells 23,402 Shares

By GuruFocus Research 05-28-2023